JAZZ — Jazz Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $10.18bn
- $13.49bn
- $4.07bn
- 71
- 62
- 78
- 81
Annual income statement for Jazz Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,364 | 3,094 | 3,659 | 3,834 | 4,069 |
| Cost of Revenue | |||||
| Gross Profit | 2,215 | 2,653 | 3,119 | 3,399 | 3,623 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,991 | 2,924 | 3,725 | 3,256 | 3,352 |
| Operating Profit | 373 | 170 | -65.5 | 579 | 717 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 275 | -113 | -373 | 298 | 470 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 242 | -329 | -214 | 418 | 562 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 239 | -330 | -224 | 415 | 560 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 239 | -330 | -224 | 440 | 571 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 10.9 | -3.03 | 7.18 | 7.09 | 8.8 |